Skip to content
CancerIndex

Publication

Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction.

E Massy, N Stacoffe, M Fauvernier, M Duruisseaux, E Grolleau, M Lamkhioued, M Pérol, C Domblides, M Roche, A Stuani, P Clézardin, E Bonnelye, J B Pialat, N Girard, C Confavreux

Journal of bone oncologyOct 1, 2026PMID 42662853doi:10.1016/j.jbo.2026.100797 PMC13520977Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 16, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260916-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

INTRODUCTION: Patients with bone metastases (BM) from non-small cell lung cancer (NSCLC) derive less clinical benefit from immune checkpoint inhibitors (ICIs) than those without skeletal involvement. We aimed to characterize bone-specific disease control profiles under first-line ICI therapy and…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.